ELIZABETH COULSON: Open Payments
NPI 1487251930 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$365 in 19 payments from 11 companies in 2025. Trend: 2023 $146 · 2024 $363 · 2025 $365
Food & beverage: $365
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 4 | $74 |
| Gilead Sciences, Inc. | 3 | $67 |
| E.R. Squibb & Sons, L.L.C. | 2 | $37 |
| Luye Pharma (USA) Ltd. | 2 | $33 |
| ABBVIE INC. | 2 | $31 |
| Neurocrine BioSciences, Inc. | 1 | $25 |
| ViiV Healthcare Company | 1 | $24 |
| Lilly USA, LLC | 1 | $21 |
| Alkermes, Inc. | 1 | $21 |
| Indivior Inc. | 1 | $16 |
Products named: REXULTI, COBENFY, ERZOFRI EXTENDED-RELEASE, INGREZZA, APRETUDE, MOUNJARO, ARISTADA, ABILIFY MAINTENA.
Industry payments across IN — which companies pay providers there.
